Skip to content
Politically.com Search all
Menu

2025 · 2nd Quarter (Apr 1 - June 30)

ALKERMES, INC.

Filed by SPLITOAK STRATEGIES LLC.

Open official filing
Source: Lobbying Disclosure APIRecently refreshed. 2026-08-03 06:26:15 UTC.

Source-reported fields

Filing overview

Type
2nd Quarter - Report
Posted
Jul 21, 2025
Income
$50,000.00
Expenses
Not reported
Filing UUID
3e38d6e7-f1de-48f1-972c-1df0f4de4890
Termination date
Not reported

Literal source text

Lobbying issues and bill citations

HCR · Health Issues

Support patient-centered care and treatment that ensures comprehensive care and access to all FDA approved treatments for substance use disorder and alcohol use disorder; Initiatives to promote the use of relapse prevention post detoxification; Advance the use and funding of FDA-approved medicines to treat serious mental illness in criminal justice and public health settings; H.R. 4030, Treatment Continuity Act of 2025

Literal federal measure citations: H.R. 4030

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.